Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9Y3A0
UPID:
COQ4_HUMAN
Alternative names:
Coenzyme Q biosynthesis protein 4 homolog
Alternative UPACC:
Q9Y3A0; A8WBK8; B2R958; Q5T4B8; Q96EW4
Background:
Ubiquinone biosynthesis protein COQ4 homolog, mitochondrial, also known as Coenzyme Q biosynthesis protein 4 homolog, plays a crucial role in the coenzyme Q biosynthetic pathway. It is instrumental in organizing a multi-subunit COQ enzyme complex essential for coenzyme Q biosynthesis and maintaining steady-state levels of other COQ polypeptides.
Therapeutic significance:
The protein is linked to Coenzyme Q10 deficiency, primary, 7, a severe disorder stemming from mitochondrial dysfunction, characterized by low levels of coenzyme Q10 and life-threatening cardiac or neurologic symptoms. Understanding the role of Ubiquinone biosynthesis protein COQ4 homolog could open doors to potential therapeutic strategies for this condition.